Stereotaxis Inc. (STXS) announced Monday that it received regulatory approval of its Niobe remote magnetic technology for cardiac ablations in Japan.
Stereotaxis gapped up Monday and has risen above the morning's narrow range in the last few minutes on increased volume. The stock is now up 0.43 at $2.22. Stereotaxis has climbed to a 2-week high and has re-crossed both its 50 and 200-day moving averages.
For comments and feedback: editorial@rttnews.com